Chitosan nanoplatform for the co-delivery of palbociclib and ultra-small magnesium nanoclusters: dual receptor targeting, therapy and imaging

Simple item page
dc.contributor.authorMehata A.K.
dc.contributor.authorSingh V.
dc.contributor.authorVikas
dc.contributor.authorSrivastava P.
dc.contributor.authorKoch B.
dc.contributor.authorKumar M.
dc.contributor.authorMuthu M.S.
dc.date.accessioned2025-01-13T07:09:03Z
dc.date.available2025-01-13T07:09:03Z
dc.date.issued2024
dc.description.abstractTheranostic nanoparticles have gained significant attention in cancer diagnosis and therapy. In this study, estrone (ES) and folic acid (FA) functionalized single and dual receptor targeted theranostic chitosan nanoparticles were developed for breast cancer imaging and therapy. These nanoparticles (NPs) were loaded with palbociclib (PB) and ultra-small magnesium nanoclusters (UMN). The developed nontargeted theranostic NPs (PB-UMN-CS-NPs), estrogen receptor targeted theranostic NPs (PB-UMN-CS-ES-NPs), folate receptor targeted theranostic NPs (PB-UMN-CS-FA-NPs), and dual targeted theranostic NPs (PB-UMN-CS-ES-FA-NPs) have particle sizes of 178.4 � 1.21 nm, 181.6� 1.35 nm, 185.1� 1.33 nm, and 198.2� 1.43 nm with surface charges of +19.02� 0.382 mV, +13.89�0.410 mV, +16.72�0.527 mV and +15.23�0.377 mV, respectively. Cytotoxicity studies on estrogen receptor (ER) and folate receptor (FR) expressing breast cancer cells revealed that dual-targeted theranostic NPs (PB-UMN-CS-FA-ES-NPs) were more effective, inhibiting cell growth by 54.17 and 42.23 times in MCF-7 and T-47D cells compared to free PB, respectively. Additionally, developed NPs were capable of inhibiting the cell cycle progression of MCF-7 cells from the G1 phase to the S phase more efficiently compared to free PB. Ultrasound and photoacoustic (USG/PA) imaging demonstrated that dual targeted theranostic NPs were capable of effectively reducing hypoxic tumor volume and significantly suppressing tumor vascularity compared to free PB, nontargeted, FR targeted and ER targeted NPs. Moreover, in vivo optical imaging demonstrated tumor specific accumulation of the dual-targeted theranostic NPs. Furthermore, in vitro hemocompatibility and histopathological studies confirmed the biocompatibility of developed nanoformulations. � The author(s).
dc.identifier.doi10.7150/ntno.94364
dc.identifier.issn22067418
dc.identifier.urihttps://dl.bhu.ac.in/ir/handle/123456789/3508
dc.language.isoen
dc.publisherIvyspring International Publisher
dc.subjectchitosan nanoparticles
dc.subjectbreast cancer
dc.subjectdual receptor targeting
dc.subjectoptical and ultrasound/photoacoustic imaging
dc.subjecttheranostics
dc.titleChitosan nanoplatform for the co-delivery of palbociclib and ultra-small magnesium nanoclusters: dual receptor targeting, therapy and imaging
dc.typeArticle
journal.titleNanotheranostics
journalvolume.identifier.volume8

Files

Collections

2024